Kapur committed to customers, partners, healthcare community with innovative solutions
Chicago’s Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, has entered into a Supply and Distribution Agreement with one of India’s premier organizations, Aimil Ltd, a leader in introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India.
“Heart disease is a global problem and Cardio Diagnostics’ expansion to India underscores our commitment to combat heart disease globally. We are thrilled to partner with Aimil on our first international expansion,” said Meesha Dogan Ph.D., CEO and Co-Founder of Cardio Diagnostics.
“This expansion is possible because Cardio Diagnostics’ clinical tests are developed with scalability in mind with respect to operations and costs, enabling deployment across diverse healthcare landscapes worldwide, to play a transformative role in mitigating heart disease globally.”
Cardiovascular disease (CVD) remains the leading cause of death in India, with the nation facing alarmingly high incidences. According to the Global Burden of Disease study by the Institute for Health Metrics and Evaluation, the age-standardized CVD death rate in India is 282 deaths per 100,000 people, which is markedly higher than the global average of 233 deaths per 100,000 people.
Studies have reported that Indians develop heart disease nearly a decade earlier than their European counterparts, with approximately 62% of heart disease related deaths among Indians being premature. This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics’ clinical test, PrecisionCHD, for the detection and personalized management of coronary heart disease (CHD).
The first phase of this collaboration will focus on pre-marketing, laying the groundwork for a successful product introduction to Aimil’s extensive healthcare network. Cardio Diagnostics and Aimil intend to further expand the Supply and Distribution Agreement after a successful phase one, to ensure that customers in India have consistent and reliable access to Cardio Diagnostics’ groundbreaking diagnostic test.
“We are excited to collaborate with Cardio Diagnostics to introduce the first epigenetics-based heart disease diagnostic technology to India. As a leader in the healthcare industry, Aimil is committed to empowering our customers, partners, and the healthcare community in India with innovative solutions to tackle heart disease,” said Dr. Mallika Kapur, Executive Director of Aimil.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.
Aimil was founded in 1932, with a mission to bring leading edge technologies to India. With 14 sales and service offices across India, 1,000+ employees, NABL certified testing and calibration laboratories, and manufacturing, R&D & software development capability, Aimil offers value-added distribution to overseas companies wanting to expand professionally in India. Fiinews.com
